Lv3
366 积分 2025-04-08 加入
Iptacopan: First Approval
13天前
已完结
Atrasentan: First Approval
13天前
已完结
Iptacopan in IgA Nephropathy — Final 24-Month Data
1个月前
已完结
Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy
1个月前
已完结
Atrasentan: First Approval
1个月前
已完结
Atrasentan in patients with IgA nephropathy (ALIGN): final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial
1个月前
已完结
Sibeprenlimab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial
1个月前
已完结
Telitacicept for IgA Nephropathy — Interim Analysis of a Phase 3 Trial
1个月前
已完结
[The standardization process and clinical challenges in the diagnosis and treatment of IgA nephropathy in China:commentary on the clinical practice guidelines for adult patients with IgA nephropathy and IgA vasculitis-associated nephritis in China (2025)]
1个月前
已完结
[Clinical practice guidelines for adult patients with IgA nephropathy and IgA vasculitis-associated nephritis in China (2025)]
1个月前
已完结
皖公网安备34019202002308
